Provid US-Based Drug Discovery Service Capabilities
- Close interaction with collaborators’ biologists, chemists
- Hypothesis-driven R&D strategy
- Approach designed for target & objectives
- Hit-to-lead, lead optimization iterative cycles
- Modeling, structure-based drug design, SAR
- Chemical process research; translation to API
- Management of third parties and collaborators
- All therapeutic areas and compound types
- Special expertise in small molecule synthetic chemistry, medicinal chemistry, prodrugs, and peptide mimetics
Licensed for DEA schedule IV research
SBIR/STTR Eligible
Bridging the Gap Between Research and Drug Development
Expert Medicinal Chemistry
Provid expert drug discovery and development services
- Medicinal chemistry lead optimization
- Translate hits into viable lead candidates
- Prodrug expertise
- Process research and support for scale-up synthesis
- Multiple compound classes (e.g., small molecules, peptide mimetics)
…all pointing to the value of Provid’s deep expertise in medicinal chemistry and drug discovery
Experience over a wide range of translational R&D from academia
Extensive experience supporting biotech/pharma
Contact us to discuss your project and to request a proposal
Therapeutic Expertise and Target Classes
Therapeutic areas
- Autoimmune disease
- Oncology
- Infectious disease
- Inflammation/Asthma
- Obesity
- Neurodegeneration
- Cardiovascular disease
- Radioprotection
- Ophthalmology
- Neurology-ADHD
Compound classes and targets
- Peptides and peptide mimetics
- Small molecule drugs
- Natural products
- RNA Polymerase Inhibitors
- Prodrugs and targeted therapeutics
- Protein-protein interactions
- Receptors
- GPCR and allosteric ligands
- Immune MHCs
- Enzyme inhibitors
- Kinase inhibitors (multiple)
Client drug discovery projects
Biotech/Pharma
- Sequenom—Isoform specific AKAP/PKA inhibitors
- NCI Developmental Therapeutics—CHK2 inhibitors (SBIR Contract)
- Palatin Technologies–drug candidate for obesity (licensed to Astra Zeneca)
- Arginetix/Corridor–arginase inhibitor (acquired by Astra Zeneca)
- Alcon–(stable CNP agonist); company acquired by Novartis
- Rutgers–RNA polymerase (R. Ebright, Rutgers) 5 yr NIH grant
- AECOM–prostaglandin transport inhibitor program (licensed by PGTi Inc.)
- Oncoceutics/Chimerix–(ONC201, ONC206, ONC212) medchem discovery, process R&D collaboration; deuterated standards
- Supernus–multiple prodrug programs (neurology, CNS)
- Escape Bio–prodrugs of Parkinson’s drug candidate
Academia
- University of Pennsylvania
- Penn State Hershey
- Duke University
- Rutgers/HHMI
- Albert Einstein College of Medicine
- University of Virginia
- U. Massachusetts Medical Center
- University of California San Diego
- University of Medicine and Dentistry of New Jersey
- University of Bordeaux
- Children’s Hospital Boston
- Pohang University (KR)
- State University of New York Downstate
- Columbia University
- Brown University
- University of Texas, San Antonio
NIH Grant Support
Provid is a US-based drug discovery company entirely located in New Jersey and is SBIR/STTR grant eligible.
Examples include the following.
Grant Funding
- NIAID SBIR and R01: Antibacterial RNAP inhibitors (Rutgers/HHMI)
- NINDS STTR: Inhibitors of polyQ aggregation (Huntington’s) (Duke)
- NHLBI SBIR: F11R Inhibitors for Atherosclerosis (SUNY Downstate)
- NHLBI SBIR: Inhibitors of PKA localization in heart (UCSD)
- NIDDK SBIR: Celiac disease, MHC class II DQ2 inhibitors (Oslo)
- NJCST: Postdoctoral fellowship, drug design algorithms (Rutgers)
- NINDS SBIR: Multiple sclerosis, MHC class II DR2 inhibitors blocking antigen presentation (Case Western, UTSA)
- Fast Forward/NMSS: PV-267 for multiple sclerosis (UTSA)
- NJEDA: Autoimmune disease (Springboard Fund; Edison Venture)
- NCI SBIR: Trail upregulation by TIC10 analogs (Fox Chase, Brown, Oncoceutics)
- NCI SBIR: Smurf-2 inhibitors to stabilize HIF-1a (submitted)